Skip to content
Screener

BioCryst Pharmaceuticals BCRX Shares issuable under the employee stock purchase plan

Shares issuable under the employee stock purchase plan at other companies

AMN Healthcare logo
AMN HealthcareAMN
-$57K
AMN Healthcare logo
AMN HealthcareAMN
-$57K
Cboe Global Markets logo
Cboe Global MarketsCBOE
$5M+4.2%
Flywire Corporation logo
Flywire CorporationFLYW
$834.5K+7.4%
Flywire Corporation logo
Flywire CorporationFLYW
$834.5K+7.4%
Doximity logo
DoximityDOCS
$1.19M-30.9%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.4B+39.2%
Enterprise value$2.65B+40.4%
P/S2.6×-0.5×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net income (loss) per common share: basic$0.31$0.02$(2.59)$0.02
Effect of dilutive securities:
Stock options to purchase common stock5,2276,3605,380
Unvested restricted stock unit awards5,4123,9732,966
Shares issuable under the employee stock purchase plan453425
Dilutive potential common shares10,68410,3678,371
Weighted average shares of common stock outstanding: diluted265,165219,886248,403217,574
Net income (loss) per common share: diluted$0.30$0.02$(2.59)$0.02

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's shares issuable under the employee stock purchase plan?
BioCryst Pharmaceuticals (BCRX) reported shares issuable under the employee stock purchase plan of 45K in Q2 2026.
How has BioCryst Pharmaceuticals's shares issuable under the employee stock purchase plan changed year-over-year?
BioCryst Pharmaceuticals's shares issuable under the employee stock purchase plan increased by 32.4% year-over-year, from 34K to 45K.
What does shares issuable under the employee stock purchase plan mean?
Represents the number of common shares reserved for issuance to employees through stock purchase plans, typically offered at a discount. This metric highlights the potential future dilution resulting from employee equity incentive programs.

Ask your AI about BioCryst Pharmaceuticals's shares issuable under the employee stock purchase plan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude